BlueRock Therapeutics’ Post

🚀 Together for innovation: Charité - Universitätsmedizin Berlin and Bayer AG have unveiled plans for the Berlin Center for Gene and Cell Therapies, a new hub aimed at accelerating groundbreaking gene and cell therapies. 🌟 With substantial support from the German federal government and the State of Berlin, this initiative seeks to make advanced treatments more accessible to patients and establish Berlin as a leading biotech ecosystem. 🔬 The center will feature an incubator supporting #startups in developing innovative therapeutic approaches, complete with fully equipped lab spaces and GMP-certified production facilities. 🤝 Together, Charité and Bayer are committed to transforming promising research into real-world health solutions. 👉 Discover more about the thriving health economy in the Berlin Brandenburg Airport Region and the medicine of the future here: https://lnkd.in/egk3uZ74 #AirportRegionBB #Biotech #MedicalResearch #FutureOfMedicine

AI Impact on Biotools and CGT In my recent webinar, I hosted Bryan Poltilove, former Operating Partner with BroadOak Capital Partners and VP/GM Cell & Gene Therapy at Thermo Fisher Scientific, to discuss raising capital with private equity and a strategic. In this segment, Bryan discusses the impact of AI on the cell therapy space. For the full webinar, click the link in the comments. I'm committed to continuing this complimentary series and covering a variety of topics for leaders in the Life Science Tools and Molecular Diagnostics domains. If you would like to stay informed on future webinars, please send me a message with your contact information. #startups #lifesciences #lifesciencetools #biopharma 

AI Impact on Biotools and CGT In my recent webinar, I hosted Bryan Poltilove, former Operating Partner with BroadOak Capital Partners and VP/GM Cell & Gene Therapy at Thermo Fisher Scientific, to discuss raising capital with private equity and a strategic. In this segment, Bryan discusses the impact of AI on the cell therapy space. For the full webinar, click the link in the comments. I'm committed to continuing this complimentary series and covering a variety of topics for leaders in the Life Science Tools and Molecular Diagnostics domains. If you would like to stay informed on future webinars, please send me a message with your contact information. #startups #lifesciences #lifesciencetools #biopharma 

PRECISION FUNCTIONAL GENOMICS, THE FUTURE OF DIAGNOSTICS AND THERAPEUTICS OncoDxRx’s circulating cell-free transcriptomics program, a commitment toward precision functional genomics, has three set objectives: - Bridge the gap of tumor-only, labor-intensive and costly cell-free DNA based technologies; - Personalize precision diagnostic capacities with implementation of patient-derived gene expression signatures; - Rationalize therapy selection and drug-response monitoring with insights from both tumor and non-tumor microenvironment. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Scaling Innovation: Swiss Biotech’s Hiring Surge in 2025 ⭐ View our latest Industry Analytics Report, produced using independent data from our exclusive partnership with Vacancysoft, the UK's leading provider of labour market data and analytics. Switzerland’s biotech landscape in 2025 is set to be vibrant and rapidly evolving, fuelled by strong domestic innovation and global trends in pharmaceuticals and life sciences. The country’s biotech sector has been steadily expanding, with many small to mid-sized companies making significant strides in areas such as oncology, gene therapy, and precision medicine. These firms are well-positioned to drive forward new breakthroughs, reinforcing Switzerland’s status as a key hub for biotech innovation. https://lnkd.in/eTtfme2 #lifesciences #switzerland

Scaling Innovation: Swiss Biotech’s Hiring Surge in 2025 ⭐ View our latest Industry Analytics Report, produced using independent data from our exclusive partnership with Vacancysoft, the UK's leading provider of labour market data and analytics. Switzerland’s biotech landscape in 2025 is set to be vibrant and rapidly evolving, fuelled by strong domestic innovation and global trends in pharmaceuticals and life sciences. The country’s biotech sector has been steadily expanding, with many small to mid-sized companies making significant strides in areas such as oncology, gene therapy, and precision medicine. These firms are well-positioned to drive forward new breakthroughs, reinforcing Switzerland’s status as a key hub for biotech innovation. https://lnkd.in/eTtfme2 #lifesciences #switzerland

Scaling Innovation: Swiss Biotech’s Hiring Surge in 2025 ⭐ View our latest Industry Analytics Report, produced using independent data from our exclusive partnership with Vacancysoft, the UK's leading provider of labour market data and analytics. Switzerland’s biotech landscape in 2025 is set to be vibrant and rapidly evolving, fuelled by strong domestic innovation and global trends in pharmaceuticals and life sciences. The country’s biotech sector has been steadily expanding, with many small to mid-sized companies making significant strides in areas such as oncology, gene therapy, and precision medicine. These firms are well-positioned to drive forward new breakthroughs, reinforcing Switzerland’s status as a key hub for biotech innovation. https://lnkd.in/eTtfme2z #lifesciences #switzerland

🧬 #𝗺𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 & #𝗖𝗚𝗧 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴? ◽𝗺𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 & 𝗖𝗚𝗧 𝘀𝘁𝗮𝗿𝘁-𝘂𝗽𝘀 𝗱𝗼𝘂𝗯𝗹𝗲 𝘁𝗵𝗲𝗶𝗿 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝘃𝗼𝗹𝘂𝗺𝗲 𝗶𝗻 𝗤𝟯 𝘃𝘀. 𝗤𝟮 𝟮𝟬𝟮𝟰. 19 companies could secure a total of $484M in Q3 2024, representing almost double the amount raised in Q2 2024 according to the American Society of Gene & Cell Therapy. Let's hope that seed & series A financings keep on rebounding in the advanced therapies field! ◽ 𝗚𝗲𝗻𝗲 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 ｜ 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗡𝗲𝘄𝘀 Follow me for more breaking research & news.

Offering 'stability' for your research😉

Pharma Insights 2024! Stay ahead of the curve with these rare pharma facts: - Gene editing: CRISPR technology has been used to develop a treatment for sickle cell disease, with promising results in clinical trials. - AI-powered drug discovery: A new AI platform has identified potential treatments for Alzheimer's disease, showcasing the power of machine learning in pharma. - Personalized medicine: Advances in genetic testing have enabled tailored treatments for cancer patients, improving efficacy and reducing side effects. - Sustainable pharma: The industry is shifting towards eco-friendly manufacturing processes, reducing waste and environmental impact. - Global collaboration: International partnerships have accelerated vaccine development, demonstrating the power of collective innovation. Share your thoughts on these breakthroughs! #Pharma2024 #Innovation #GeneEditing #AI #PersonalizedMedicine #Sustainability